Your session is about to expire
← Back to Search
Gene Therapy
AGT103-T for HIV/AIDS
Phase 1
Waitlist Available
Research Sponsored by American Gene Technologies International Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up days 1 to 180 post-infusion
Awards & highlights
Summary
This trial tests a new treatment where a patient's own immune cells are modified to better fight HIV. It targets people with HIV who have their virus under control with medication.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ days 1 to 180 post-infusion
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~days 1 to 180 post-infusion
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Assess the safety of AGT103-T in HIV+ participants with well-controlled viremia on antiretroviral therapy: adverse events
Trial Design
2Treatment groups
Experimental Treatment
Group I: Low Dose CohortExperimental Treatment1 Intervention
A single infusion of ≥1x10e8 and <1x10e9 genetically modified T cells.
Group II: High Dose CohortExperimental Treatment1 Intervention
A single infusion of ≥1x10e9 and <5x10e9 genetically modified T cells.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
AGT103-T
2020
Completed Phase 1
~10
Find a Location
Who is running the clinical trial?
American Gene Technologies International Inc.Lead Sponsor
3 Previous Clinical Trials
38 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger